Evidence map›Paper›PMID 29245892›Full record

ArticleOncotarget2017

MEK/ERK addiction in CNL/aCML.

Meenu Kesarwani, Zachary Kincaid, Mohammad Azam

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Current Management of Chronic Neutrophilic Leukemia.Current treatment options in oncology · 2021
    Review
  3. Atypical Chronic Myeloid Leukemia: Where Are We Now?International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Meenu KesarwaniMohammad Azam: Division of Experimental Hematology and Division of Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Zachary KincaidMohammad Azam: Division of Experimental Hematology and Division of Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Mohammad AzamMohammad Azam: Division of Experimental Hematology and Division of Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Funding

Improved therapeutic approaches for hematological disorder treated with tyrosineR01CA155091 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI AZAM, MOHAMMAD · 2012 to 2016
$1.6M
NCI NIH HHS R01 CA155091
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

aCMLCNLERK1/2KSR1Trametinib

Identifiers

PMID29245892
PMCPMC5725083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.